Oncology Brothers: Practice-Changing Cancer Discussions How to Treat Hormone Receptor Positive Cancer - Latest Advancements and Current Standard of Care in 2025
Feb 24, 2025
In this enlightening discussion, Dr. Kevin Kalinsky, a leading breast medical oncologist and director of the breast cancer program at Emory University's Winship Cancer Institute, shares groundbreaking insights into the treatment of hormone receptor-positive breast cancer. He emphasizes the role of OncotypeDX in determining chemotherapy for different menopausal statuses and delves into the promising implications of new therapies like Inavolisib and CDK4-6 inhibitors. The conversation also explores genomic assays and ongoing trials that may reshape future treatment protocols.
AI Snips
Chapters
Transcript
Episode notes
Use OncotypeDX By Menopausal Status
- Use OncotypeDX to guide chemo decisions but tailor by menopausal status and node involvement.
- Order the recurrence score early if helpful, but reconsider if surgical nodes show higher involvement.
Ordering Recurrence Score Before Surgery
- Dr Kalinsky described ordering recurrence score before surgery for a patient who wanted the test.
- He cancelled the test after surgical nodes showed more extensive involvement.
Combine Genomics With Clinical Features
- Stick with one genomic assay per ASCO guidance and integrate clinical features for decisions.
- RS-Clin and MammaPrint both work, but RS-Clin offers helpful clinical-pathologic integration.